Medifast (NYSE:MED) Director Parsa Kiai Purchases 43,150 Shares

Medifast Inc (NYSE:MED) Director Parsa Kiai purchased 43,150 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were acquired at an average price of $12.26 per share, with a total value of $529,019.00. Following the completion of the transaction, the director owned 707,492 shares of the company’s stock, valued at approximately $8,673,851.92. This trade represents a 6.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Monday, August 24th, Parsa Kiai acquired 4,329 shares of Medifast stock. The stock was bought at an average price of $12.00 per share, for a total transaction of $51,948.00.
• On Thursday, August 20th, Parsa Kiai acquired 43,150 shares of Medifast stock. The stock was bought at an average price of $11.60 per share, for a total transaction of $500,540.00.
• On Wednesday, August 19th, Parsa Kiai bought 29,337 shares of Medifast stock. The stock was bought at an average cost of $11.66 per share, with a total value of $342,069.42.

Medifast Price Performance

Shares of MED stock opened at $12.17 on Friday. The business has a 50-day moving average of $11.00 and a 200 day moving average of $11.10. Medifast Inc has a 1-year low of $9.22 and a 1-year high of $14.67. The stock has a market capitalization of $136.06 million, a PE ratio of -5.22 and a beta of 0.65.

Medifast (NYSE:MED) last announced its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.The business had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Analysts anticipate that Medifast Inc will post -1.04 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on MED shares. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $12.00.

Institutional Investors Weigh In On Medifast

A number of large investors have recently made changes to their positions in MED. BlackRock Inc. purchased a new position in shares of Medifast during the second quarter valued at approximately $3,920,000. Lido Advisors LLC purchased a new stake in Medifast in the third quarter worth $4,521,000. Steamboat Capital Partners LLC bought a new stake in Medifast in the fourth quarter valued at $2,952,000. Charles Schwab Investment Management Inc. boosted its holdings in Medifast by 30.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock valued at $8,297,000 after acquiring an additional 181,618 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Medifast by 37.4% during the 2nd quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock valued at $5,569,000 after purchasing an additional 107,854 shares during the period. 95.51% of the stock is currently owned by institutional investors.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.